Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies.

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Quality of life in MPN comes of age as a therapeutic target.

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Letter to Our Readers.

The future of JAK inhibition in myelofibrosis and beyond.

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.